Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2009

01.04.2009

Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis

verfasst von: Gianfranco Lessiani, Angela Falco, Elvira Nicolucci, Giancarlo Rolandi, Giovanni Davì

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Factor XII deficiency is associated with increased risk for both arterial and venous thrombosis. We describe a case of DVT involving superficial femoral and popliteal vein occurred following total hip replacement and despite prophylaxis with low molecular weight heparin in a subject with previous acute myocardial infarction (AMI). Tests of haemostasis documented a slightly prolonged activated partial thromboplastin time (APTT) (45′′) due to mild factor XII deficiency (clotting activity 32%). A therapeutic dose of enoxaparin was started, together with warfarin therapy. The patient was advised to continue oral anticoagulation indefinitely. Although cases of both venous and arterial thrombosis in carriers of severe factor XII deficiency have been already reported, to our knowledge this is the first case in the literature occurred in a carrier of partial factor XII deficiency. In conclusion, factor XII deficiency should be suspected if a patient presents with recurrent arterial and/or venous thrombosis and prolonged APTT. If this defect is diagnosed, in the presence of a history of thrombotic events, lifelong anticoagulation could be considered.
Literatur
1.
Zurück zum Zitat Colman RW, Schmaier AH (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90:3819–3843PubMed Colman RW, Schmaier AH (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90:3819–3843PubMed
2.
Zurück zum Zitat Kohler HP, Carter AM, Stickland MH, Grant PJ (1998) Levels of activated FXII in survivors of myocardial infarction—association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 79:14–18PubMed Kohler HP, Carter AM, Stickland MH, Grant PJ (1998) Levels of activated FXII in survivors of myocardial infarction—association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 79:14–18PubMed
3.
Zurück zum Zitat Halbmayer WM, Haushofer A, Schon R, Mannhalter C, Strohmer E, Baumgarten K, Fischer M (1994) The prevalence of moderate and severe factor XII deficiency among the normal population: evaluation of the incidence of factor XII deficiency among 300 healthy blood donors. Thromb Haemost 71:68–72PubMed Halbmayer WM, Haushofer A, Schon R, Mannhalter C, Strohmer E, Baumgarten K, Fischer M (1994) The prevalence of moderate and severe factor XII deficiency among the normal population: evaluation of the incidence of factor XII deficiency among 300 healthy blood donors. Thromb Haemost 71:68–72PubMed
4.
Zurück zum Zitat Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO (2004) Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 137:459–464PubMedCrossRef Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO (2004) Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 137:459–464PubMedCrossRef
5.
Zurück zum Zitat Pandita D, Steen P, Potti A (1997) Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 127:1129PubMed Pandita D, Steen P, Potti A (1997) Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 127:1129PubMed
6.
Zurück zum Zitat Koster T, Rosendaal FR, Briet E, Vandenbroucke JP (1994) John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia study. Br J Haematol 87:422–424PubMedCrossRef Koster T, Rosendaal FR, Briet E, Vandenbroucke JP (1994) John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia study. Br J Haematol 87:422–424PubMedCrossRef
7.
Zurück zum Zitat Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 17:139–143PubMedCrossRef Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 17:139–143PubMedCrossRef
8.
Zurück zum Zitat Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C (2005) Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 11:49–53PubMedCrossRef Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C (2005) Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 11:49–53PubMedCrossRef
9.
Zurück zum Zitat Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lämmle B (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families. Thromb Haemost 82:1240–1246PubMed Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lämmle B (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families. Thromb Haemost 82:1240–1246PubMed
10.
Zurück zum Zitat von Kanel R, Wuillemin WA, Furlan M, Lämmle B (1992) Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 3:555–561CrossRef von Kanel R, Wuillemin WA, Furlan M, Lämmle B (1992) Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 3:555–561CrossRef
11.
Zurück zum Zitat Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M (1992) The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 68:285–290PubMed Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M (1992) The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 68:285–290PubMed
12.
Zurück zum Zitat Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M (1994) Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery. Coron Artery Dis 5:451–454PubMedCrossRef Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M (1994) Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery. Coron Artery Dis 5:451–454PubMedCrossRef
13.
Zurück zum Zitat Doggen CJ, Rosendaal FR, Meijers JC (2006) Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108:4045–4051PubMedCrossRef Doggen CJ, Rosendaal FR, Meijers JC (2006) Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108:4045–4051PubMedCrossRef
14.
Zurück zum Zitat Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C (2007) Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 5:1143–1148PubMedCrossRef Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C (2007) Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 5:1143–1148PubMedCrossRef
15.
Zurück zum Zitat Bombeli T, Jutzi M, De Conno E, Seifert B, Fehr J (2002) In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins. Blood Coagul Fibrinolysis 13:577–581PubMedCrossRef Bombeli T, Jutzi M, De Conno E, Seifert B, Fehr J (2002) In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins. Blood Coagul Fibrinolysis 13:577–581PubMedCrossRef
16.
Zurück zum Zitat Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ (2000) Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 102:2058–2062PubMed Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ (2000) Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 102:2058–2062PubMed
17.
Zurück zum Zitat Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A (1995) Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136:5076–5083PubMedCrossRef Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A (1995) Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136:5076–5083PubMedCrossRef
18.
Zurück zum Zitat Kanaji T, Kanaji S, Osaki K, Kuroiwa M, Sakaguchi M, Mihara K, Niho Y, Okamura T (2001) Identification and characterization of two novel mutations (Q421 K and R123P) in congenital factor XII deficiency. Thromb Haemost 86:1409–1415PubMed Kanaji T, Kanaji S, Osaki K, Kuroiwa M, Sakaguchi M, Mihara K, Niho Y, Okamura T (2001) Identification and characterization of two novel mutations (Q421 K and R123P) in congenital factor XII deficiency. Thromb Haemost 86:1409–1415PubMed
19.
Zurück zum Zitat Ishii K, Oguchi S, Moriki T, Yatabe Y, Takeshita E, Murata M, Ikeda Y, Watanabe K (2004) Genetic analyses and expression studies identified a novel mutation (W486C) as a molecular basis of congenital coagulation factor XII deficiency. Blood Coagul Fibrinolysis 15:367–373PubMedCrossRef Ishii K, Oguchi S, Moriki T, Yatabe Y, Takeshita E, Murata M, Ikeda Y, Watanabe K (2004) Genetic analyses and expression studies identified a novel mutation (W486C) as a molecular basis of congenital coagulation factor XII deficiency. Blood Coagul Fibrinolysis 15:367–373PubMedCrossRef
20.
Zurück zum Zitat Oguchi S, Ishii K, Moriki T, Takeshita E, Murata M, Ikeda Y, Watanabe K (2005) Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency. Thromb Res 115:191–197PubMedCrossRef Oguchi S, Ishii K, Moriki T, Takeshita E, Murata M, Ikeda Y, Watanabe K (2005) Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency. Thromb Res 115:191–197PubMedCrossRef
21.
Zurück zum Zitat Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y (1998) A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 91:2010–2014PubMed Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y (1998) A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 91:2010–2014PubMed
22.
Zurück zum Zitat Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, Felices R, Borrell M, Fontcuberta J (2004) Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 91:899–904PubMed Tirado I, Soria JM, Mateo J, Oliver A, Souto JC, Santamaria A, Felices R, Borrell M, Fontcuberta J (2004) Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 91:899–904PubMed
23.
Zurück zum Zitat Santamaría A, Martínez-Rubio A, Mateo J, Tirado I, Soria JM, Fontcuberta J (2004) Homozygosity of the T allele of the 46C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 89:878–879PubMed Santamaría A, Martínez-Rubio A, Mateo J, Tirado I, Soria JM, Fontcuberta J (2004) Homozygosity of the T allele of the 46C-->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 89:878–879PubMed
Metadaten
Titel
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis
verfasst von
Gianfranco Lessiani
Angela Falco
Elvira Nicolucci
Giancarlo Rolandi
Giovanni Davì
Publikationsdatum
01.04.2009
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2009
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-008-0222-1

Weitere Artikel der Ausgabe 3/2009

Journal of Thrombosis and Thrombolysis 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.